Background: Discordant results in conventional susceptibility testing of ethambutol against Mycobacterium tuberculosis may lead to underreporting of drug resistance.
Methods: A 240-bp region of the embB gene in 111 clinical isolates of M. tuberculosis was sequenced and examined for mutations linked to ethambutol resistance. The phenotypic susceptibility levels of the isolates were quantified by the BACTEC™ MGIT 960™ TB System and correlated with the genotypic test results. These data were analyzed to find information that could be used to clarify discordant ethambutol susceptibility test results.
Results: Mutations M306I (n = 56), M306V (n = 18) and M306L (n = 3) in M. tuberculosis showed decreased susceptibility to ethambutol. The minimum inhibitory concentrations (MICs) in 73% (56/77) of embB306 mutants were at or just above the critical concentration (MICs, 5.0 to ≤12.5 µg/ml) of ethambutol reflecting borderline (or intermediate) resistance. Eight ethambutol-resistant isolates lacked embB mutations, probably due to mutational alterations elsewhere in the genome.
Conclusion: Our findings suggest that clinical isolates containing embB306 mutations with MICs overlapping the critical concentration are associated with discordant ethambutol susceptibility test results. The clinical significance of borderline resistance in combination treatment of tuberculosis remains to be determined before alternative ethambutol breakpoints are considered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000343474 | DOI Listing |
Tuberculosis (Edinb)
January 2025
Latvian Biomedical Research and Study Centre, Ratsupites street 1, k-1, Riga, LV-1067, Latvia; Riga Stradiņš University, Pharmacogenetic and Precision Medicine Laboratory, Konsula street 21, Riga, LV-1007, Latvia. Electronic address:
Biomarker research characterising the effect of anti-tuberculosis (TB) chemotherapy on systemic body response is still limited. In this study, we aimed to investigate fluctuations in circulating cell-free mitochondrial DNA (ccf-mtDNA) and circulating cell-free nuclear DNA (ccf-nDNA) copy number (CN) in blood plasma of patients with drug-susceptible TB (DS-TB) and to decipher factors related to these fluctuations. The results showed considerable changes in ccf-mtDNA CN in plasma samples before drug intake and 2 and 6 h afterwards, with high inter patient variability at each time point.
View Article and Find Full Text PDFInfect Dis Clin Microbiol
December 2024
Department of Medical Pharmacology, Sivas Cumhuriyet University Faculty of Medicine, Sivas, Türkiye.
Objective: Tuberculosis (TB) is a public health problem. This study aimed to determine the growth rates and drug susceptibility levels of patients with complex (MTC) growth in cultures obtained and to compare the results with the growth rates and drug susceptibility levels found in our country and other countries. It also aimed to evaluate the results of supplementing classical methods such as Lowenstein-Jensen (LJ) with liquid TK MEDIUM and to determine the relationship between the growth rates obtained with both methods.
View Article and Find Full Text PDFCureus
November 2024
Pulmonology, Unidade Local de Saúde Amadora/Sintra, Amadora, PRT.
Introduction The prevalence of nontuberculous mycobacteria (NTM) is higher in patients with structural lung disease and in immunocompromised patients. Lung involvement is the most common. The complex corresponds to the most identified agent.
View Article and Find Full Text PDFPol J Vet Sci
September 2024
Department of Food Hygiene and Public Health Protection, Institute of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776 Warsaw, Poland.
The material for drug resistance testing was 28 strains of Mycobacterium caprae isolated from tissue collected post mortem from a free-living Bieszczady Mountain European bison (Bison bonasus caucasicus) herd. All drug susceptibility tests were carried out on an automated Bactec mycobacterial growth indicator tube (MGIT) 960 system, using Bactec MGIT 960 streptomycin, isoniazid, rifampin and ethambutol (S.I.
View Article and Find Full Text PDFInt J Antimicrob Agents
December 2024
Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
Objective: Mycobacterium avium complex bacteria cause chronic pulmonary disease (MAC-PD) in susceptible patients. The recommended treatment regimen (rifampicin, ethambutol and azithromycin) achieves 65% cure rates but with considerable toxicity and drug-drug interactions [2,3]. Minocycline proved active in monotherapy experiments using the hollow-fibre model [4].
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!